These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 8639800)

  • 1. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
    Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
    Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells.
    Daniel PT; Kroidl A; Kopp J; Sturm I; Moldenhauer G; Dörken B; Pezzutto A
    Blood; 1998 Dec; 92(12):4750-7. PubMed ID: 9845541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
    Haagen IA
    Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
    Manzke O; Tesch H; Lorenzen J; Diehl V; Bohlen H
    Int J Cancer; 2001 Feb; 91(4):516-22. PubMed ID: 11251975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies.
    De Gast GC; Van Houten AA; Haagen IA; Klein S; De Weger RA; Van Dijk A; Phillips J; Clark M; Bast BJ
    J Hematother; 1995 Oct; 4(5):433-7. PubMed ID: 8581381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
    Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
    Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
    Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
    J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
    De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
    J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation.
    Manzke O; Tesch H; Borchmann P; Wolf J; Lackner K; Gossmann A; Diehl V; Bohlen H
    Int J Cancer; 2001 Feb; 91(4):508-15. PubMed ID: 11251974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibody treatment of murine B cell lymphoma.
    De Jonge J; Heirman C; De Veerman M; Van Meirvenne S; Demanet C; Brissinck J; Thielemens K
    Cancer Immunol Immunother; 1997; 45(3-4):162-5. PubMed ID: 9435864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
    Csóka M; Strauss G; Debatin KM; Moldenhauer G
    Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies.
    Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Asano R; Ichiyama M; Imai K; Hinoda Y; Matsuno S; Kudo T
    Immunol Lett; 2002 Apr; 81(2):99-106. PubMed ID: 11852114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.
    Brissinck J; Demanet C; Moser M; Leo O; Thielemans K
    J Immunol; 1991 Dec; 147(11):4019-26. PubMed ID: 1940384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
    Renner C; Pfreundschuh M
    J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
    Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
    J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome.
    Honeychurch J; Cruise A; Tutt AL; Glennie MJ
    Cancer Immunol Immunother; 1997; 45(3-4):171-3. PubMed ID: 9435866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.